Fludarabine in the Treatment of Lymphoproliferative Malignancies

References

• Schauer P, Arlin Z, Mertelsmann R, Cirrincione C. Treatment of acute leukemia in adults: Results of the L-10 and L-10M protocols. J Clin Oncol 1983; 1: 462–470
   PubMed Web of Science ®Google Scholar
• Skarin AT., Canellos G P, Rosenthal D S. Improved prognosis of diffuse histocytic and undifferential lymphoma by the use of high dose methotrexate alternating with standard agent CM-Bacid. J Clin Oncol 1983; l: 91
   Google Scholar
• Sawitsky A., Rai K B, Glidewell C. Comparison of daily versus intermittent chlorambucil corticosteroid therapy in the treatment of patients with chronic lymphocytic leukemia. Blood 1977; 50: 1049–1059
   PubMed Web of Science ®Google Scholar
• Grever MR., Leiby J M, Kraut E H. Low dose deoxycofor-mycin in lymphoid malignancy. J Clin Oncol 1985; 3: 1196–1201
   PubMed Web of Science ®Google Scholar
• Piro L D, Carrera C J, Beutler E. 2-Chlorodeoxyadenosine: An effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988; 72: 1069–1073
   PubMed Web of Science ®Google Scholar
• Hutton J J, VonHoff D D, Kuhn J. Phase I clinical investigation of 9-B-D-arabinofuranosyl-2-fluoroadenine 5′mono-phosphate (NSC 312887). a new purine antimetabolite. Cancer Res 1984; 44: 4183–4186
   PubMed Web of Science ®Google Scholar
• Tseng W, Derse C. D., Cheng Y C. In vitro activity of 9-B-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide re-ductase from HeLa cells. Pharmacology 1982; 21: 474–477
   Web of Science ®Google Scholar
• Plunkett W., Chubb S. Toxicity, metabolism and incorporation into DNA and RNA of arabinosyl-2-fluoroadenine (F-ara-A). Proc Am Assoc Cancer Res 1985; 26: 19
   Web of Science ®Google Scholar
• Snyder R D, Van Houten B, Regan J D. The inhibition of ultraviolet radiation induced DNA repair in human diploid fibro-blasts by arabinofuronasyl nucleosides. Chem Biol Interact 1984; 50: 1–14
   PubMed Web of Science ®Google Scholar
• Spriggs D., Robbiiis G, Mitchell T. Incorporation of 9-B-D-arabinosyl-2-fluoroadenine in HL-60 cellular RNA and DNA. Biochem Pharmacol 1986; 35: 247–252
   PubMed Web of Science ®Google Scholar
• VonHoff D. Phase I clinical trials with fludarabine phosphate. Semin Oncol 1990; 17: 33–38, Suppl. 8
   Web of Science ®Google Scholar
• Warrell R P, Berrnan E. Phase I and II study of fludarabine phosphate in leukemia. Therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol 1986; 4: 74
   PubMed Web of Science ®Google Scholar
• Grever M R, Coltman CA., Files J L. Fludarabine mono-phosphate in chronic lymphocytic leukemia. Blood 1986; 68: 223a
   Google Scholar
• Grever M, Kopecky R. LJ., Coltman C A. Fludarabine mono-phosphate: A potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol 1988; 30: 457–459
   PubMedGoogle Scholar
• Keating M, Kantarjian J. H, Talpaz M. Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19–25
   PubMed Web of Science ®Google Scholar
• Cheson B D, Bennett J M, Rai K R. Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute Sponsored Working Group. Am J Hematol 1988; 39: 152–163
   Google Scholar
• Keating M J, Kantarjian H M, O'Brien S. Fludarabine (FLU)-prednisone (PRED): A safe effective combination in refractory chronic lymphocytic leukemia. Proc Am Soc Clin Oncol 1989; 8: 201
   Google Scholar
• Puccio C, Mittelman A. A, Lichtman S M. A loading dose/ continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia. J Clin Oncol 1991; 9: 1562–1569
   PubMed Web of Science ®Google Scholar
• Keating M., Kantarjian H, O'Brien S. Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 1991; 9: 44–49
   PubMed Web of Science ®Google Scholar
• Leiby J M, Snider K M, Kraut E H. Phase 11 trial of 9-B-D-arabinfuranosyl-2-fluoroadenine 5′-monophosphate in non-Hodgkin's lymphoma: Prospective comparison of response with deoxycytidine kinase activity. Cancer Res 1987; 47: 2719–2722
   PubMed Web of Science ®Google Scholar
• Hochster H, Cassileth P. Fludarabine phosphate therapy of non-Hodgkin's lymphoma. Semin Oncol 1990; 17: 63–65
   PubMed Web of Science ®Google Scholar
• Redrnan J, Cabanillas F, McLaughlin P. Fludarabine phosphate: A new agent with major activity in low grade lymphoma. Proc Am Assoc Clin Res 1988; 29: 211, abstract
   Web of Science ®Google Scholar
• Kantarjian H, Alexanian R, Koller C A. Fludarabine therapy in macroglobulinemic lymphoma. Blood 1990; 75: 1928–1931
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Childs C, O'Brien S. Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with pro-lymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia. Am J Med 1991; 90: 223–228
   PubMed Web of Science ®Google Scholar
• Boldt D, Von Hoff H. DD., Kahn J G. Effects on human peripheral lymphocytes of in vivo administration of 9-B-D-arabinofuranocy-2-fluoroabinosine-5′ monophosphate (NSC 312887). a new purine antimetabolite. Cancer Res 1984; 44: 4661–4666
   PubMed Web of Science ®Google Scholar
• Von Hoff D, Dahlberg S, Hartsock R. Evaluation of fludarabine monophosphate in patients with advanced mycosis fungoides: A Southwest Oncology Group study. Proc Am Soc Clin Oncol 1989; 8: 269
   Google Scholar
• Kantarjian H G, Redman J R, Keating M J. Fludarabine phosphate therapy in other lymphoid malignancies. Semin Oncol 1990; 17: 66–70
   PubMed Web of Science ®Google Scholar
• Kraut E H, Grever M R, Salmon S. Phase II trial of fludarabine phosphate in multiple myeloma. Proc Am Assoc Cancer Res 1989; 30: 1052
   Google Scholar
• Anaissie E, Kontoyiannis J. DP., O'Brien S., Robertson L E, Bodey G, Keating P. M. The changing spectrum of infections in patients with chronic lymphocytic leukemia (CLL). Proc lntersci Conf Antimicrob Agents Chemother. Chicago 1991, abstract
   Google Scholar
• Robertson L, Huh E. Y, Hirsch-Ginsberg C., Kantarjian H., O'Brien S. C, McKoller A., Credie K B, Keating M J. Clinical immunophe-notypic. and molecular analysis of the completeness of response in chronic lymphocytic leukemia after fludarabine. Am Soc Hematol 1990; 76: 314, abstract
   Google Scholar
• Kraut E H, Neff J C, Bouroncle B A. Immunosuppressive effects of pentostatin. J Clin Oncol 1990; 8: 848–855
   PubMed Web of Science ®Google Scholar
• Hurst P G, Habib M P, Garewal H. Pulmonary toxicity with fludarabine monophosphate. Invest New Drugs 1987; 5: 207–210
   PubMed Web of Science ®Google Scholar
• List A F, Kummet T D, Adarns J D. Tumor lysis syndrome complicating treatment of chronic lymphocytic leukemia with fludarabine phosphate. Am J Med 1991; 88: 389–390
   Google Scholar
• Han T, Ezdinli E Z, Shimaoka K, Desai D V. Chlorambucil vs. combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemia. Cancer 1973; 31: 502
   PubMed Web of Science ®Google Scholar
• Kempin S, Lee B J, Thaler H T. Combination chemotherapy of advanced chronic lymphocytic leukemia: The M-2 protocol (vincristine, BCNU, cyclophosphamide, melphalan and predni-sone). Blood 1982; 60: 1110
   PubMed Web of Science ®Google Scholar
• Keating M, Scouros J. M, Murphy S. Multiple agent chemotherapy (POACH) in previously treated and untreated patients with chronic lymphocytic leukemia. Leukemia 1988; 2: 157
   PubMed Web of Science ®Google Scholar
• Losada A P, Wessman M, Tiainen M. Trisomy 12 in chronic lymphocytic leukemia: An interphase cytogenetic study. Blood 1991; 78: 1775–779
   Google Scholar
• Gandhi V, Nowak B, Keating M J. Modulation of arabi-nosylctosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: Implications for combination therapy. Blood 1989; 74: 2070–2075
   PubMed Web of Science ®Google Scholar